MetaVia

MetaVia Payables Turnover

The Payables Turnover Ratio of MetaVia (MTVA) as of Oct 21, 2026 is 0.02. In the previous year, Payables Turnover Ratio was 0.01 — a change of 189.71% (higher).

Payables Turnover

0.02

YoY

189.71%

Last updated:

Payables Turnover Ratio of MetaVia is 2025 0.02 . Payables Turnover Ratio of MetaVia was 2024 0.01 . It decreases by 189.71% higher compared to the previous year.

The MetaVia Payables Turnover history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Payables Turnover
Date
Payables Turnover
Jan 1, 2020
0.03 USD
Jan 1, 2021
0.09 USD
Jan 1, 2022
0.04 USD
Jan 1, 2023
0.01 USD
Jan 1, 2024
0.01 USD
Jan 1, 2025
0.02 USD
The MetaVia Payables Turnover history
YEARPayables TurnoverYoY
0.02+189.71%
0.01-27.43%
0.01-78.44%
0.04-54.41%
0.09+233.39%
0.03—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

MetaVia Stock analysis

What does MetaVia do? NeuroBo Pharmaceuticals, Inc. generates revenue by developing novel pharmaceuticals to address unmet medical needs in patients suffering from neurodegenerative disorders. The company focuses on specific therapeutic areas including Painful Diabetic Neuropathy (PDN) and Alzheimer’s disease, targeting these conditions with its proprietary product candidates. This strategy allows the firm to serve the clinical-stage biotechnology market by offering specialized treatments for serious health conditions. The company’s product portfolio includes NB-01, which is designed to target neuropathic pain with an indication for PDN, and NB-02, a drug developed for Alzheimer’s and tauopathies. Additionally, the firm offers Gemcabene, a therapy focused on treating dyslipidemia, a condition that increases the risk of life-threatening cardiovascular disease. Gemcabene is specifically directed at orphan indications such as homozygous familial hypercholesterolemia (HoFH) and severe hypertriglyceridemia (SHTG). Furthermore, NeuroBo Pharmaceuticals, Inc. is developing a capsule formulation of niclosamide for coronavirus indications. By expanding its research into these diverse medical conditions, the company aims to provide comprehensive pharmaceutical solutions. The firm operates from its headquarters in Boston, Massachusetts, and maintains a focused development pipeline to bring these treatments to market. MetaVia is one of the most popular companies on Eulerpool.

Frequently Asked Questions about MetaVia stock

Payables Turnover Ratio of MetaVia is 0.02 in 2025.

Payables Turnover Ratio of MetaVia changed from 0.01 to 0.02, representing a 189.71% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Payables Turnover Ratio MetaVia since 2006 – with annual values, charts, and detailed analysis.

Payables turnover measures how quickly a company pays its suppliers. Lower turnover may indicate better payment terms or cash flow management.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Payables Turnover Ratio's MetaVia with sector peers and the industry average to assess whether it is attractive.

To evaluate Payables Turnover Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Payables Turnover Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — MetaVia

All Key Metrics — MetaVia